Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

COVID-19 in patients with chronic lymphocytic leukemia: a multicenter analysis by the Czech CLL study group

M. Šimkovič, P. Turcsányi, M. Špaček, J. Mihályová, P. Ryznerová, M. Maco, P. Vodárek, D. Écsiová, H. Poul, H. Móciková, J. Zuchnická, A. Panovská, M. Lekaa, M. Oršulová, A. Prchlíková, L. Stejskal, S. Mašlejová, Y. Brychtová, L. Bezděková, T....

. 2023 ; 102 (4) : 811-817. [pub] 20230227

Jazyk angličtina Země Německo

Typ dokumentu multicentrická studie, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc23003639

Patients with chronic lymphocytic leukemia (CLL) have a high risk of poor outcomes related to coronavirus disease 2019 (COVID-19). This multicenter cohort study evaluated the impact of COVID-19 infection on the population of CLL patients in the Czech Republic. Between March 2020 and May 2021, 341 patients (237 males) with CLL and COVID-19 disease were identified. The median age was 69 years (range 38-91). Out of the 214 (63%) patients with the history of therapy for CLL, 97 (45%) were receiving CLL-directed treatment at diagnosis of COVID-19: 29% Bruton tyrosine kinase inhibitor (BTKi), 16% chemoimmunotherapy (CIT), 11% Bcl-2 inhibitor, and 4% phosphoinositide 3-kinase inhibitor. Regarding the severity of COVID-19, 60% pts required admission to the hospital, 21% pts were admitted to the intensive care unit (ICU), and 12% received invasive mechanical ventilation. The overall case fatality rate was 28%. Major comorbidities, age over 72, male gender, CLL treatment in history, CLL-directed treatment at COVID-19 diagnosis were associated with increased risk of death. Of note, concurrent therapy with BTKi compared to CIT was not associated with better outcome of COVID-19.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc23003639
003      
CZ-PrNML
005      
20240122102143.0
007      
ta
008      
230418s2023 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00277-023-05147-z $2 doi
035    __
$a (PubMed)36847805
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Šimkovič, Martin $u 4th Department of Internal Medicine - Hematology, Faculty of Medicine in Hradec Králové, University Hospital and Charles University in Prague, Prague, Czech Republic. simkovicm@lfhk.cuni.cz $1 https://orcid.org/0000000303315334 $7 xx0117538
245    10
$a COVID-19 in patients with chronic lymphocytic leukemia: a multicenter analysis by the Czech CLL study group / $c M. Šimkovič, P. Turcsányi, M. Špaček, J. Mihályová, P. Ryznerová, M. Maco, P. Vodárek, D. Écsiová, H. Poul, H. Móciková, J. Zuchnická, A. Panovská, M. Lekaa, M. Oršulová, A. Prchlíková, L. Stejskal, S. Mašlejová, Y. Brychtová, L. Bezděková, T. Papajík, D. Lysák, M. Trněný, L. Smolej, M. Doubek
520    9_
$a Patients with chronic lymphocytic leukemia (CLL) have a high risk of poor outcomes related to coronavirus disease 2019 (COVID-19). This multicenter cohort study evaluated the impact of COVID-19 infection on the population of CLL patients in the Czech Republic. Between March 2020 and May 2021, 341 patients (237 males) with CLL and COVID-19 disease were identified. The median age was 69 years (range 38-91). Out of the 214 (63%) patients with the history of therapy for CLL, 97 (45%) were receiving CLL-directed treatment at diagnosis of COVID-19: 29% Bruton tyrosine kinase inhibitor (BTKi), 16% chemoimmunotherapy (CIT), 11% Bcl-2 inhibitor, and 4% phosphoinositide 3-kinase inhibitor. Regarding the severity of COVID-19, 60% pts required admission to the hospital, 21% pts were admitted to the intensive care unit (ICU), and 12% received invasive mechanical ventilation. The overall case fatality rate was 28%. Major comorbidities, age over 72, male gender, CLL treatment in history, CLL-directed treatment at COVID-19 diagnosis were associated with increased risk of death. Of note, concurrent therapy with BTKi compared to CIT was not associated with better outcome of COVID-19.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a kohortové studie $7 D015331
650    12
$a COVID-19 $x komplikace $7 D000086382
650    _2
$a testování na COVID-19 $7 D000086742
650    12
$a chronická lymfatická leukemie $x farmakoterapie $x epidemiologie $7 D015451
650    _2
$a fosfatidylinositol-3-kinasy $7 D019869
650    _2
$a ženské pohlaví $7 D005260
651    _2
$a Česká republika $x epidemiologie $7 D018153
655    _2
$a multicentrická studie $7 D016448
655    _2
$a časopisecké články $7 D016428
700    1_
$a Turcsányi, Peter $u Department of Haematology-Oncology, University Hospital, Olomouc, Czech Republic
700    1_
$a Špaček, Martin $u First Department of Medicine - Haematology, University General Hospital, Prague, Czech Republic
700    1_
$a Mihályová, Jana $u Department of Hematooncology, University Hospital, Ostrava, Czech Republic
700    1_
$a Ryznerová, Pavlína $u Department of Haematology-Oncology, University Hospital, Olomouc, Czech Republic
700    1_
$a Maco, Mária $u Department of Internal Medicine - Haematology, University Hospital Královské Vinohrady, Prague, Czech Republic $7 xx0312295
700    1_
$a Vodárek, Pavel $u 4th Department of Internal Medicine - Hematology, Faculty of Medicine in Hradec Králové, University Hospital and Charles University in Prague, Prague, Czech Republic
700    1_
$a Écsiová, Dominika $u 4th Department of Internal Medicine - Hematology, Faculty of Medicine in Hradec Králové, University Hospital and Charles University in Prague, Prague, Czech Republic
700    1_
$a Poul, Hynek $u Department of Hematology and Transfusion Medicine, Hospital Pelhrimov, Pelhrimov, Czech Republic
700    1_
$a Móciková, Heidi $u Department of Internal Medicine - Haematology, University Hospital Královské Vinohrady, Prague, Czech Republic
700    1_
$a Zuchnická, Jana $u Department of Hematooncology, University Hospital, Ostrava, Czech Republic
700    1_
$a Panovská, Anna $u Department of Internal Medicine - Haematology and Oncology, University Hospital, Brno, Czech Republic
700    1_
$a Lekaa, Mohammad $u Department of Hematology and Oncology, Medical School and Teaching Hospital in Plzen, Charles University in Prague, Plzen, Czech Republic
700    1_
$a Filipová, Martina $u Department of Internal Medicine - Haematology and Oncology, University Hospital, Brno, Czech Republic $7 xx0313005
700    1_
$a Prchlíková, Adéla $u Department of Internal Medicine - Haematology and Oncology, University Hospital, Brno, Czech Republic $7 xx0310412
700    1_
$a Stejskal, Lukáš $u Haematology/Tranfusiology Department, Silesian Hospital Opava, Opava, Czech Republic
700    1_
$a Mašlejová, Stanislava $u Department of Internal Medicine - Haematology and Oncology, University Hospital, Brno, Czech Republic
700    1_
$a Brychtová, Yvona $u Department of Internal Medicine - Haematology and Oncology, University Hospital, Brno, Czech Republic
700    1_
$a Bezděková, Lucie $u Department of Internal Medicine - Haematology and Oncology, University Hospital, Brno, Czech Republic
700    1_
$a Papajík, Tomáš $u Department of Haematology-Oncology, University Hospital, Olomouc, Czech Republic
700    1_
$a Lysák, Daniel $u Department of Hematology and Oncology, Medical School and Teaching Hospital in Plzen, Charles University in Prague, Plzen, Czech Republic
700    1_
$a Trněný, Marek $u First Department of Medicine - Haematology, University General Hospital, Prague, Czech Republic
700    1_
$a Smolej, Lukáš $u 4th Department of Internal Medicine - Hematology, Faculty of Medicine in Hradec Králové, University Hospital and Charles University in Prague, Prague, Czech Republic
700    1_
$a Doubek, Michael $u Department of Internal Medicine - Haematology and Oncology, University Hospital, Brno, Czech Republic
773    0_
$w MED00000424 $t Annals of hematology $x 1432-0584 $g Roč. 102, č. 4 (2023), s. 811-817
856    41
$u https://pubmed.ncbi.nlm.nih.gov/36847805 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20230418 $b ABA008
991    __
$a 20240122102141 $b ABA008
999    __
$a ok $b bmc $g 1924361 $s 1189848
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2023 $b 102 $c 4 $d 811-817 $e 20230227 $i 1432-0584 $m Annals of hematology $n Ann Hematol $x MED00000424
LZP    __
$a Pubmed-20230418

Najít záznam

Citační ukazatele

Možnosti archivace